Leerink raised the firm’s price target on Cardinal Health (CAH) to $156 from $138 and keeps an Outperform rating on the shares. Q2 results ...

Cardinal's pharmaceutical and specialty solutions segment distributes branded, generic, and specialty drugs and over-the-counter healthcare and consumer products. Cardinal plays a central role in the ...

Cardinal Health reported an increase in revenue for two of its segments, while the departure of Optimum impacted its Pharmaceuticals segment.

Dublin City Schools has officially backed out of a deal to acquire the vacant Cardinal Health office building, pivoting ...

Cardinal Health has reported second quarter revenue for its “other” businesses, which includes at-Home Solutions, increased 13% to $1.3 billion.

Drug distributor Cardinal Health on Thursday raised its fiscal 2025 adjusted profit forecast as strong demand for costly specialty medicines and branded drugs drove sales at its pharmaceuticals unit.

Cardinal expects full-year earnings to be $7.85 to $8 per share. Cardinal shares have climbed 8% since the beginning of the year, while the S&P's 500 index has climbed 27%. The stock has risen 20% in ...